Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.40 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.40 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13482023 | 0.87 | KCNA4 (0.34) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1471940 | 0.77 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL14649692 | 0.77 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL3545805 | 0.77 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL21061213 | 0.74 | POLB (0.38) | — | |
| SCHEMBL13208899 | 0.74 | KCNA4 (0.34) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL3505529 | 0.72 | POLB (0.36) | — | |
| SCHEMBL21216529 | 0.72 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL15481094 | 0.72 | — | — | |
| SCHEMBL13897204 | 0.72 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| CN-117673460-A | DOX monomer-based in-situ polyelectrolyte, preparation method and application thereof | 华南师范大学 | 2024-03-08 | — | — | CN | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| US-20220402862-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | INTELLIA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| US-7344583-B2 | Methods of making metal particles within cored dendrimers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20050244561-A1 | Carvone acetals used as flavourings | SYMRISE GMBH & CO. KG (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1529095-A1 | CARVONE ACETALS USED AS FLAVOURINGS | Symrise GmbH & Co. KG (DE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004015044-A1 | CARVONE ACETALS USED AS FLAVOURINGS | SYMRISE GMBH & CO. KG (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-4209444-A | INHIBITORS OF AGGREGATION OR ADHESION OF THROMBOCYTES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | KCNA4 2700/4885KCNA1 4709/4885KCNAB1 4645/4885 |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | PRDX2, PRDX1, PRDX5 | KCNA4 4470/4885KCNA1 4367/4885KCNAB1 4600/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | KCNA4 2283/4885KCNA1 3031/4885KCNAB1 3122/4885 |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | ETV6, PKD1, PKD2 | KCNA4 237/4885KCNA1 376/4885KCNAB1 402/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | KCNA4 2283/4885KCNA1 3031/4885KCNAB1 3122/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | KCNA4 709/4885KCNA1 636/4885KCNAB1 852/4885 |
| US-20220402862-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | PHOSPHO1, SGMS1, SGMS2 | KCNA4 1266/4885KCNA1 2173/4885KCNAB1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.